HilleVax, Inc.

NASDAQ•HLVX

CEO: Dr. Robert M. Hershberg M.D., Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2022-04-29

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

連絡先情報

321 Harrison Avenue, 5th floor, Boston, MA, 02118, United States

617-213-5054

www.hillevax.com

時価総額

$104.76M

PER (TTM)

-2.3

24.5

配当利回り

52週高値

$2.17

52週安値

$1.34

52週レンジ

90%

順位58Top 85.6%

2.3

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 2.3 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q2 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.11-86.75%

直近4四半期の推移

フリーCF

-$789.00K-97.36%

直近4四半期の推移

2025 Q2 決算ハイライト

主なハイライト

R&D Spending Significantly Reduced Six-month R&D expenses fell $49.3M to $3.311M, driven by HIL-214 discontinuation decisions in 2024.

Net Loss Improvement Strong Net loss for six months narrowed substantially to $(11.327)M versus $(87.497)M last year due to lower operating costs.

Cash Position At Period End Total cash, cash equivalents, and restricted cash stood at $60.308M as of June 30, 2025, supporting operations.

Operating Cash Use Decreased Net cash used in operating activities decreased to $(13.507)M for six months, down from $(62.781)M previously.

リスク要因

XOMA Merger Closing Risk Transaction completion depends on Minimum Cash Condition ($103.0M) and tender offer thresholds being met by Merger Sub.

CVR Payment Uncertainty Holders may not receive payment on Contingent Value Rights (CVRs) if specified events do not occur or CVRs expire.

Liquidity Runway Limited Existing cash supports operations for next 12 months; failure to raise capital impacts future development timelines.

Merger Restrictions Impact Operations Merger Agreement imposes limitations on business activities, asset disposal, and debt incurrence without XOMA consent.

見通し

XOMA Acquisition Anticipated Closing Acquisition by XOMA via cash tender offer and Merger is anticipated to close in September 2025.

Continue Strategic Alternatives Review Company continues to explore and evaluate development of remaining vaccine candidates and business development activities.

Future Capital Needs Uncertain Future financing will rely on equity offerings, debt, or collaborations to fund costly clinical trial progress.

Takeda License Termination Notice Written notice delivered to terminate Takeda License; termination effective six months after notice delivery date.

同業比較

売上高 (TTM)

TRML

$40.00K

-98.2%

HLVX

$0.00

-100.0%

粗利益率 (最新四半期)

HLVX

0.0%

+0.0pp

TRML

0.0%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
TRML	$1.23B	-18.1	-24.4%	0.1%
HLVX	$104.76M	-2.3	-30.0%	13.5%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし